ReviewFrontiers in oncology2026
Hypoxia-regulated non-coding RNAs in OSCC liquid biopsy: from molecular mechanisms to AI-driven precision oncology.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Oral squamous cell carcinoma (OSCC) is characterized by late-stage diagnosis and high recurrence rates. Intratumoral hypoxia, driven by hypoxia-inducible factors 1α and 2α (HIF-1α/HIF-2α), orchestrates aggressive phenotypes including epithelial-mesenchymal transition (EMT), metabolic reprogramming, stemness maintenance, and therapeutic resistance. Non-coding RNAs (ncRNAs) serve as central post-transcriptional regulators of these hypoxic adaptations and offer promising non-invasive biomarker potential. Methods: A systematic literature search of the PubMed database was executed on May 15, 2026, using structured Boolean combinations of Medical Subject Headings (MeSH) terms and high-accuracy text keywords targeting OSCC, hypoxia pathways (HIF-1α/HIF-2α), non-coding RNA classes (miRNAs, lncRNAs, circRNAs), and liquid biopsy media (saliva, plasma, serum, exosomes). Results: Hypoxic stress stabilizes HIF-1α during acute oxygen deprivation and HIF-2α during chronic adaptation, driving widespread dysregulation across the non-coding transcriptome. HIF-1α-activated "hypoxemirs" (e.g., miR-210) and oncogenic lncRNAs (MALAT1, H19, HOTAIR) coordinate early glycolytic switching and invasive EMT cascades. Conversely, chronic HIF-2α activation regulates specific downstream targets (e.g., lncRNA RAB11B-AS1, NEAT1) linked to persistent microvascular remodeling and cancer stem cell preservation. Closed-loop circular RNAs (e.g., circCDR1as, hsa-circ-0001030) display enhanced structural resistance to exonuclease degradation and act as molecular sponges within competing endogenous RNA (ceRNA) networks. When encapsulated within extracellular vesicles (exosomes) or secreted into saliva and blood, these stable transcripts provide a longitudinal window into tumor microenvironment dynamics. Incorporating artificial intelligence (AI) machine learning models improves multi-transcript signature filtering, while microfluidic point-of-care (POC) devices offer a practical roadmap for decentralized diagnostic deployment. Conclusion: Hypoxia-responsive ncRNAs isolated from liquid biopsies represent promising candidates for OSCC precision oncology. However, routine clinical translation remains restricted as most candidate biomarkers are currently in Phase 1 discovery or Phase 2 early biofluid validation stages. Widespread clinical adoption is limited by pre-analytical sample handling variability, a lack of universally stable internal reference controls, cohort heterogeneity, insufficient prospective multi-center validation, and regulatory approval barriers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.